Reduced transthyretin expression in sera of lung cancer

Cancer Science

Volumn 98, Issue 10, 2007, Pages 1617-1624

  Liu, Liyun ^a,b   Liu, Jifu ^c   Dai, Songwei ^a,b   Wang, Xiaomin ^a,b   Wu, Shanshan ^c   Wang, Jianing ^a,b   Huang, Lingyun ^a,b   Xiao, Xueyuan ^a,b   He, Dacheng ^a,b  

^a BEIJING NORMAL UNIVERSITY   (China)

^b Universities' Confederated Institute of Proteomics   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PREALBUMIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPRECIPITATION; LUNG CANCER; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WESTERN BLOTTING;

ADENOCARCINOMA; AMINO ACID SEQUENCE; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOPRECIPITATION; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PREALBUMIN; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 34548165577     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00576.x     Document Type: Article

References (44)

1. Chen G, Gharib TG, Wang H et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA 2003; 100: 13 537-42.
2. Granville CA, Dennis PA. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 2005; 32: 169-76.
3. Xiao T, Ying W, Li L et al. An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics 2005; 4: 1480-6.
4. Kulpa J, Wojcik E, Reinfuss M et al. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA21-1, and neuro-specific enolase in squamous cell lung cancer patients. Clin Chem 2002; 48: 1931-37.
5. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 2002; 122: 1037-57.
6. Yu Y, Chen S, Wang LS et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 2005; 68: 79-86.
7. Ward DG, Cheng Y, Kontchou GN et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer 2006; 94: 287-92.
8. Ward DG, Suggett N, Cheng Y et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006; 94: 1898-905.
9. Adam BL, Qu Y, Davis JW et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609-14.
10. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7.
11. Chen YD, Zheng S, Yu JK et al. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 2004; 10: 8380-5.
12. Valle RP, Chavany C, Zhukov TA et al. New approaches for biomarker discovery in lung cancer. Expert Rev Mol Diagn 2003; 3: 55-67.
13. Xiao X, Liu D, Tang Y et al. Development of proteomic patterns for detecting lung cancer. Dis Markers 2004; 19: 33-9.
14. Power DM, Elias NP, Richardson SJ et al. Evolution of the thyroid hormone-binding protein, transthyretin. Gen Comp Endocrinol 2000; 119: 241-55.
15. Fung ET, Yip TT, Lomas L et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005; 115: 783-9.
16. Jacobsson B, Collins VP, Grimelius L et al. Transthyretin immunoreactivity in human and porcine liver, choroid plexus, and pancreatic islets. J Histochem Cytochem 1989; 37: 31-7.
17. Itoh N, Hanafusa T, Miyagawa J et al. Transthyretin (prealbumin) in the pancreas and sera of newly diagnosed type I (insulin-dependent) diabetic patients. J Clin Endocrinol Metab 1992; 74: 1372-7.
18. Thomas JGL, Jeffrey M, Victoria M et al. Transthyretin (prealbumin) immunoreactivity in renal cell carcinoma and other neoplasms. Int J Surg Pathol 1996; 4: 1-7.
19. Menard C, Johann D, Lowenthal M et al. Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res 2006; 66: 1844-50.
20. Lowenthal MS, Mehta AI, Frogale K et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 2005; 51: 1933-45.
21. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: Spinning biologic trash into diagnostic gold. J Clin Invest 2006; 116: 26-30.
22. Geho DH, Liotta LA, Petricoin EF et al. The amplified peptidome: The new treasure chest of candidate biomarkers. Curr Opin Chem Biol 2006; 10: 50-5.
23. Raghu P, Sivakumar B. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands. implications in vitamin A homeostasis and transthyretin amyloidosis. Biochim Biophys Acta 2004; 1703: 1-9.
24. Imanishi T. Clinical and experimental studies on the profiles of serum proteins in acute hepatic injury. Gastroenterol Jpn 1981; 16: 493-505.
25. Marten NW, Sladek FM, Straus DS. Effect of dietary protein restriction on liver transcription factors. Biochem J 1996; 317: 361-70.
26. Ritchie RF, Palomaki GE, Neveux LM et al. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: A practical, simple and clinically relevant approach in a large cohort. Clin Lab Anal 1999; 13: 273-9.
27. Kozak KR, Su F, Whitelegge JP et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005; 5: 4589-96.
28. Xiao X, Zhao X, Liu J et al. Discovery of laryngeal carcinoma by serum proteomic pattern analysis. Sci Chin 2004; 47: 219-23.
29. Bagga D, Wang L, Farias-Eisner R et al. Differential effects of prostaglandin derived from -6 and -3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci USA 2003; 100: 1751-6.
30. Altland K, Winter P. Polyacrylamide gel electrophoresis followed by sodium dodecyl sulfate gradient polyacrylamide gel electrophoresis for the study of the dimer to monomer transition of human transthyretin. Electrophoresis 2003; 24: 2265-71.
31. Amareth L, Tatiana P, Mark EM et al. Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis. Protein Sci 2003; 12: 1775-85.
32. Ferlini A, Fini S, Salvi F et al. Molecular strategies in genetic diagnosis of transthyretin-related hereditory amyloidosis. FASEB J 1992; 6: 2864-6.
33. Gericke B, Raila J, Sehouli J et al. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer 2005; 5: 133.
34. Lim A, Sengupta S, McComb ME et al. In vitro and in vivo interactions of homocysteine with human plasma transthyretin. J Biol Chem 2003; 278: 49 707-13.
35. Bergen HR, Zeldenrust SR, Butz ML et al. Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem 2004; 50: 1544-52.
36. Liu DH, Wang XM, Zhang LJ et al. Serum amyloid A protein: A potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci 2007; 20: 33-40.
37. Dai SW, Wang XM, Liu LY et al. Discovery and identification of serum amyloid A protein elevated in lung cancer serum. Sci China 2007; 50: 305-11.
38. Ingenbleek Y, Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr 1994; 14: 495-533.
39. Schreiber G. The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J Endocrinol 2002; 175: 61-73.
40. Madri JA. The evolving roles of cell surface proteases in health and disease: Implications for development, adaptive, inflammatory, and neoplastic processes. Curr Top Dev Biol 2003; 54: 391-410.
41. Zucker S, Hymowitz M, Conner C et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental application. Ann NY Acad Sci 1999; 878: 212-27.
42. Bank U, Kurger S, Langner J et al. Review: Peptidases and peptidase inhibitors in the pathogenesis of diseases, disturbances in the ubiquitin-mediated proteolytic system, protease-antiprotease imbalance in inflammatory reactions, role of cathepsins in tumour progression. Adv Exp Med Biol 2000; 477: 349-78.
43. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-U-PAR-PAI-I system. Thromb Haemost 1999; 82: 298-304.
44. Zhang Z, Bast RC, Yu Y Jr et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-90.